KOO vs. INS, COG, RENX, INHC, TRLS, IQAI, FDBK, DVRG, SENS, and EMIS
Should you be buying Kooth stock or one of its competitors? The main competitors of Kooth include Instem (INS), Cambridge Cognition (COG), Renalytix (RENX), Induction Healthcare Group (INHC), Trellus Health (TRLS), IQ-AI (IQAI), Feedback (FDBK), DeepVerge (DVRG), Sensyne Health (SENS), and EMIS Group (EMIS). These companies are all part of the "health information services" industry.
Kooth vs.
Kooth (LON:KOO) and Instem (LON:INS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.
Kooth presently has a consensus target price of GBX 583.33, suggesting a potential upside of 286.57%. Given Kooth's stronger consensus rating and higher probable upside, analysts plainly believe Kooth is more favorable than Instem.
65.0% of Kooth shares are held by institutional investors. Comparatively, 65.9% of Instem shares are held by institutional investors. 17.3% of Kooth shares are held by insiders. Comparatively, 30.0% of Instem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Kooth has a net margin of 7.89% compared to Instem's net margin of 5.50%. Kooth's return on equity of 18.59% beat Instem's return on equity.
In the previous week, Instem's average media sentiment score of 0.64 beat Kooth's score of 0.59 indicating that Instem is being referred to more favorably in the news media.
Instem received 82 more outperform votes than Kooth when rated by MarketBeat users. However, 91.67% of users gave Kooth an outperform vote while only 52.25% of users gave Instem an outperform vote.
Kooth has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Instem has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
Kooth has higher earnings, but lower revenue than Instem. Instem is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.
Summary
Kooth beats Instem on 10 of the 16 factors compared between the two stocks.
Get Kooth News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOO and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
This page (LON:KOO) was last updated on 2/22/2025 by MarketBeat.com Staff